4415-05-8

Usage

Uses

Used in Medicinal Chemistry:
4-(4-Nitrophenyl)thiazole-2-carboxylic Acid is utilized as a building block or intermediate in the synthesis of various pharmaceutical compounds. Its unique structure, which includes a thiazole ring and a nitrophenyl group, allows for the development of new drugs with specific biological targets and therapeutic effects.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 4-(4-Nitrophenyl)thiazole-2-carboxylic Acid is employed as a potential candidate for drug discovery. Its chemical properties and structural features make it a valuable tool for exploring novel therapeutic agents, particularly those with potential applications in treating various diseases and conditions.
Used in Drug Development:
4-(4-Nitrophenyl)thiazole-2-carboxylic Acid is used as a key component in the design and development of new drugs. Its presence in a compound can influence pharmacokinetic and pharmacodynamic properties, such as solubility, stability, and bioavailability, which are crucial for the drug's efficacy and safety.
Used in Chemical Synthesis:
4-(4-Nitrophenyl)thiazole-2-carboxylic Acid serves as a versatile reagent in organic synthesis, enabling the creation of a wide range of chemical products. Its carboxylic acid group and nitrophenyl substituent can participate in various chemical reactions, facilitating the synthesis of complex molecules with diverse applications.

Upstream product

• 53101-04-5 ethyl 4-(4-nitrophenyl)-1,3-thiazole-2-carboxylate 
• 100-19-6 (4-nitrophenyl)ethanone 
• 99-81-0 4-Nitrophenacyl bromide 

Downstream Products

• 1300747-97-0 methyl 2-(4-(4-((6-fluorobenzo[d]thiazol-2-yl)amino)phenyl)thiazole-2-carboxamido)-3-methylbutanoate 
• 1300747-98-1 2-(4-(4-((6-fluorobenzo[d]thiazol-2-yl)amino)phenyl)thiazole-2-carboxamido)-3-methylbutanoic acid 
• 1300747-69-6 methyl 2-(4-(4-aminophenyl)thiazole-2-carboxamido)-3-methylbutanoate 
• 1300747-70-9 methyl 3-methyl-2-(4-(4-nitrophenyl)thiazole-2-carboxamido)butanoate 

Relevant academic research and scientific papers

Synthesis and evaluation of cyclohexane carboxylic acid head group containing isoxazole and thiazole analogs as DGAT1 inhibitors

Diacylglycerol acyltransferase 1 (DGAT1) is known to play an important catalytic role in the final step of triglyceride biosynthesis. High fat diet fed DGAT1 knockout mice were resistant to weight gain and exhibited increased insulin and leptin sensitivity thereby indicating a plausible role for DGAT1 inhibitors in the treatment of obesity. 4-Phenylpiperidine-1-carbonyl cyclohexanecarboxylic acid (compound 6, DGAT1 IC50 = 57 nM) has been lately reported as a potent DGAT1 inhibitor. In our search for newer scaffolds possessing potent DGAT1 activity we undertook a systematic diversification of compound 6 to identify a 4-(5-phenylthiazole-2-carboxamido)cyclohexanecarboxylic acid scaffold. Further linker optimization of this scaffold identified compound 9e (DGAT1 IC50 = 14.8 nM) as a potent DGAT1 inhibitor. Coupled with its in vitro potency, compound 9e also exhibited 112 percent plasma triglyceride reduction at a 3 mpk dose in an oral fat tolerance test (FTT) when studied in Swiss mice.

Evaluation of thiazole containing biaryl analogs as diacylglycerol acyltransferase 1 (DGAT1) inhibitors

Biphenyl carboxylic acids, exemplified by compound 5, are known potent inhibitors of diacylglycerol acyltransferase, DGAT1, an enzyme involved in the final committed step of triglyceride biosynthesis. We have synthesized and evaluated 2-phenylthiazole, 4-

HETEROARYL COMPOUNDS AS DGAT-1 1NHIBITORS

The present invention relates to novel heteroaryl compounds, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or disorders mediated by Diacylglycerol acyltransferase (DGAT) enzyme, particularly DGAT- 1.